Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6296991 | 0.90 | NR3C2 (0.45) | NR3C2CACNA1DADORA3HSD17B10ADORA2A | |
| SCHEMBL6293708 | 0.89 | CA1 (0.45) | NR3C2CACNA1DADORA3HSD17B10ADORA2A | |
| SCHEMBL6297228 | 0.88 | MEN1 (0.44) | NR3C2CACNA1DADORA3HSD17B10ALDH1A1 | |
| SCHEMBL6292289 | 0.88 | TBXA2R (0.48) | NR3C2CACNA1DADORA3HSD17B10ALDH1A1 | |
| SCHEMBL6296921 | 0.88 | NR3C2 (0.44) | NR3C2CACNA1DADORA3HSD17B10ADORA2A | |
| SCHEMBL6297263 | 0.88 | CACNA1C (0.49) | — | |
| SCHEMBL6292394 | 0.88 | DHFR (0.47) | NR3C2CACNA1DADORA3ALDH1A1ADORA2A | |
| SCHEMBL6292498 | 0.88 | NR3C2 (0.45) | NR3C2CACNA1DADORA3HSD17B10ALDH1A1 | |
| SCHEMBL6293692 | 0.87 | NR3C2 (0.42) | NR3C2CACNA1DADORA3HSD17B10ALDH1A1 | |
| SCHEMBL6292367 | 0.87 | NR3C2 (0.49) | NR3C2CACNA1DADORA3ALDH1A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | NR3C2 2858/4885CACNA1D 271/4885ADORA3 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.